Literature DB >> 29431175

Efficacy of rituximab as third-line therapy in combined central and peripheral demyelination.

Salvatore Savasta1, Thomas Foiadelli1, Elisa Vegezzi1, Andrea Cortese1, Alessandro Lozza1, Anna Pichiecchio1, Diego Franciotta1, Enrico Marchioni1.   

Abstract

Entities:  

Year:  2017        PMID： 29431175      PMCID： PMC5800713          DOI： 10.1212/CPJ.0000000000000388

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  7 in total

1.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision.

Authors: 
Journal:  J Peripher Nerv Syst       Date:  2010-12       Impact factor: 3.494

2.  A nationwide survey of combined central and peripheral demyelination in Japan.

Authors:  Hidenori Ogata; Dai Matsuse; Ryo Yamasaki; Nobutoshi Kawamura; Takuya Matsushita; Tomomi Yonekawa; Makoto Hirotani; Hiroyuki Murai; Jun-ichi Kira
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-11       Impact factor: 10.154

Review 3.  Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature.

Authors:  L Benedetti; C Briani; D Franciotta; R Fazio; I Paolasso; C Comi; M Luigetti; M Sabatelli; F Giannini; G L Mancardi; A Schenone; E Nobile-Orazio; D Cocito
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-16       Impact factor: 10.154

4.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

5.  Acute combined central and peripheral nervous system demyelination in children.

Authors:  Tanja Adamovic; Emilie M Riou; Geneviève Bernard; Michel Vanasse; Jean-Claude Décarie; Chantal Poulin; France Gauvin
Journal:  Pediatr Neurol       Date:  2008-11       Impact factor: 3.372

6.  Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.

Authors:  A Cortese; D Franciotta; E Alfonsi; N Visigalli; E Zardini; L Diamanti; P Prunetti; C Osera; M Gastaldi; G Berzero; A Pichiecchio; G Piccolo; A Lozza; G Piscosquito; E Salsano; M Ceroni; A Moglia; G Bono; D Pareyson; E Marchioni
Journal:  J Neurol Sci       Date:  2016-02-10       Impact factor: 3.181

7.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422
  7 in total
  2 in total

1.  Combined Central and Peripheral Demyelinating Disease With Good Response to B-Cell Depleting Therapy.

Authors:  Seraj Makkawi; Faisal Yonbawi; Yousef Qari; Morad Aljinaid
Journal:  Cureus       Date:  2021-04-26

2.  Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinical Applications.

Authors:  Giorgio Costagliola; Greta Depietri; Alexandre Michev; Antonella Riva; Thomas Foiadelli; Salvatore Savasta; Alice Bonuccelli; Diego Peroni; Rita Consolini; Gian Luigi Marseglia; Alessandro Orsini; Pasquale Striano
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.